Agios Pharmaceuticals Inc Financials
This page shows Agios Pharmaceuticals Inc (AGIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Agios Pharmaceuticals Inc has an operating margin of 873.9%, meaning the company retains $874 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from -1166.5% the prior year.
Agios Pharmaceuticals Inc's revenue declined 99.9% year-over-year, from $36.5M to $54K. This contraction results in a growth score of 0/100.
Agios Pharmaceuticals Inc carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 11.46, Agios Pharmaceuticals Inc holds $11.46 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Agios Pharmaceuticals Inc converts 682.4% of revenue into free cash flow ($369K). This strong cash generation earns a score of 100/100.
Agios Pharmaceuticals Inc earns a strong 34.6% return on equity (ROE), meaning it generates $35 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is down from 43.7% the prior year.
Agios Pharmaceuticals Inc scores 9308.87, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.6B) relative to total liabilities ($104K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Agios Pharmaceuticals Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Agios Pharmaceuticals Inc generates $0.90 in operating cash flow ($373K OCF vs $413K net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Agios Pharmaceuticals Inc generated $54K in revenue in fiscal year 2025. This represents a decrease of 99.9% from the prior year.
Agios Pharmaceuticals Inc's EBITDA was $472K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.1% from the prior year.
Agios Pharmaceuticals Inc generated $369K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 100.1% from the prior year.
Agios Pharmaceuticals Inc reported $413K in net income in fiscal year 2025. This represents a decrease of 99.9% from the prior year.
Agios Pharmaceuticals Inc earned $7.12 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 38.8% from the prior year.
Agios Pharmaceuticals Inc held $89K in cash against $0 in long-term debt as of fiscal year 2025.
Agios Pharmaceuticals Inc had 59M shares outstanding in fiscal year 2025. This represents an increase of 2.3% from the prior year.
Agios Pharmaceuticals Inc's gross margin was 88.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.
Agios Pharmaceuticals Inc's operating margin was 873.9% in fiscal year 2025, reflecting core business profitability. This is up 2040.3 percentage points from the prior year.
Agios Pharmaceuticals Inc's net profit margin was 764.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1081.9 percentage points from the prior year.
Agios Pharmaceuticals Inc's ROE was 34.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 9.1 percentage points from the prior year.
Agios Pharmaceuticals Inc invested $340K in research and development in fiscal year 2025. This represents a decrease of 99.9% from the prior year.
Agios Pharmaceuticals Inc invested $4K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 99.7% from the prior year.
AGIO Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.0M+55.0% | $12.9M+3.4% | $12.5M+42.7% | $8.7M-18.7% | $10.7M+19.7% | $9.0M+4.1% | $8.6M+5.2% | $8.2M |
| Cost of Revenue | $1.9M+11.9% | $1.7M-1.4% | $1.7M+56.9% | $1.1M-13.9% | $1.3M+60.9% | $783K-47.6% | $1.5M+138.4% | $627K |
| Gross Profit | $18.1M+61.5% | $11.2M+4.2% | $10.8M+40.7% | $7.6M-19.3% | $9.5M+15.8% | $8.2M+14.9% | $7.1M-5.8% | $7.6M |
| R&D Expenses | $88.1M+1.5% | $86.8M-5.6% | $91.9M+26.4% | $72.7M-12.2% | $82.8M+14.3% | $72.5M-6.4% | $77.4M+12.8% | $68.6M |
| SG&A Expenses | $51.6M+25.0% | $41.3M-10.0% | $45.9M+10.5% | $41.5M-19.7% | $51.7M+34.1% | $38.5M+8.4% | $35.5M+14.6% | $31.0M |
| Operating Income | -$121.6M-4.0% | -$116.9M+8.0% | -$127.1M-19.2% | -$106.6M+14.7% | -$125.0M-21.6% | -$102.8M+2.8% | -$105.8M-14.9% | -$92.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | N/A | N/A | N/A | $53.1M | N/A | N/A |
| Net Income | -$108.0M-4.5% | -$103.4M+7.7% | -$112.0M-25.5% | -$89.3M+7.5% | -$96.5M-110.2% | $947.9M+1086.2% | -$96.1M-17.9% | -$81.5M |
| EPS (Diluted) | $-1.86-4.5% | $-1.78+7.8% | $-1.93-24.5% | $-1.55-7.6% | $-1.44-108.9% | $16.22+1059.8% | $-1.69-16.6% | $-1.45 |
AGIO Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B-6.4% | $1.4B-5.8% | $1.5B-5.4% | $1.6B-6.5% | $1.7B-7.2% | $1.8B+131.8% | $773.1M-9.0% | $849.7M |
| Current Assets | $942.1M-8.8% | $1.0B+1.3% | $1.0B+5.2% | $968.6M+0.3% | $965.6M-10.1% | $1.1B+69.9% | $632.1M-4.7% | $663.6M |
| Cash & Equivalents | $89.1M-3.9% | $92.7M+14.6% | $80.9M+2.4% | $79.0M+3.6% | $76.2M-69.9% | $253.7M+200.2% | $84.5M-28.8% | $118.8M |
| Inventory | $32.9M+2.8% | $32.0M+3.8% | $30.8M+4.2% | $29.6M+7.2% | $27.6M+4.5% | $26.4M+10.4% | $23.9M+3.8% | $23.1M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $104.1M+2.7% | $101.4M-0.3% | $101.7M+14.3% | $89.0M-27.2% | $122.2M-26.0% | $165.1M+46.7% | $112.6M+6.4% | $105.8M |
| Current Liabilities | $82.2M+10.0% | $74.8M+6.2% | $70.4M+34.5% | $52.4M-35.5% | $81.2M-32.1% | $119.5M+90.7% | $62.6M+21.2% | $51.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.2B-7.1% | $1.3B-6.2% | $1.4B-6.6% | $1.5B-4.8% | $1.5B-5.3% | $1.6B+146.3% | $660.5M-11.2% | $743.9M |
| Retained Earnings | -$561.7M-23.8% | -$453.7M-29.5% | -$350.2M-47.0% | -$238.2M-60.0% | -$148.9M-184.2% | -$52.4M+94.8% | -$1.0B-10.6% | -$904.2M |
AGIO Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$96.2M-9.1% | -$88.2M-14.3% | -$77.1M+30.8% | -$111.5M+16.3% | -$133.2M-58.1% | -$84.2M-16.0% | -$72.6M+27.3% | -$99.9M |
| Capital Expenditures | $1.1M-28.0% | $1.6M+77.7% | $875K+14.2% | $766K-20.8% | $967K+130.8% | $419K+165.2% | $158K+12.1% | $141K |
| Free Cash Flow | -$97.3M-8.5% | -$89.7M-15.0% | -$78.0M+30.5% | -$112.3M+16.3% | -$134.1M-58.5% | -$84.6M-16.3% | -$72.7M+27.3% | -$100.0M |
| Investing Cash Flow | $90.1M-5.7% | $95.6M+21.0% | $79.0M-29.9% | $112.6M+329.0% | -$49.2M-119.6% | $250.8M+573.4% | $37.2M-70.1% | $124.6M |
| Financing Cash Flow | $2.6M-42.3% | $4.4M+6723.1% | $65K-96.0% | $1.6M-66.6% | $4.8M+83.6% | $2.6M+139.9% | $1.1M-81.3% | $5.9M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AGIO Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.6%+3.6pp | 87.0%+0.6pp | 86.3%-1.2pp | 87.6%-0.7pp | 88.3%-3.0pp | 91.3%+8.6pp | 82.7%-9.7pp | 92.3% |
| Operating Margin | -608.9%+298.5pp | -907.4%+112.7pp | -1020.1%+201.8pp | -1222.0%-56.7pp | -1165.3%-18.4pp | -1146.9%+81.4pp | -1228.3%-104.0pp | -1124.3% |
| Net Margin | -541.1%+262.0pp | -803.0%+96.3pp | -899.4%+123.9pp | -1023.3%-123.7pp | -899.6%-11474.3pp | 10574.7%+11690.4pp | -1115.7%-119.9pp | -995.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | 58.3% | N/A | N/A |
| Return on Assets | -8.3%-0.9pp | -7.5%+0.2pp | -7.6%-1.9pp | -5.7%+0.1pp | -5.8%-58.7pp | 52.9%+65.3pp | -12.4%-2.8pp | -9.6% |
| Current Ratio | 11.46-2.4 | 13.82-0.7 | 14.48-4.0 | 18.50+6.6 | 11.90+2.9 | 8.99-1.1 | 10.09-2.7 | 12.84 |
| Debt-to-Equity | 0.090.0 | 0.080.0 | 0.07+0.0 | 0.06-0.0 | 0.08-0.0 | 0.10-0.1 | 0.17+0.0 | 0.14 |
| FCF Margin | -487.5%+209.0pp | -696.5%-70.2pp | -626.3%+660.2pp | -1286.4%-36.4pp | -1250.1%-305.9pp | -944.2%-99.8pp | -844.4%+376.8pp | -1221.3% |
Similar Companies
Frequently Asked Questions
What is Agios Pharmaceuticals Inc's annual revenue?
Agios Pharmaceuticals Inc (AGIO) reported $54K in total revenue for fiscal year 2025. This represents a -99.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Agios Pharmaceuticals Inc's revenue growing?
Agios Pharmaceuticals Inc (AGIO) revenue declined by 99.9% year-over-year, from $36.5M to $54K in fiscal year 2025.
Is Agios Pharmaceuticals Inc profitable?
Yes, Agios Pharmaceuticals Inc (AGIO) reported a net income of $413K in fiscal year 2025, with a net profit margin of 764.0%.
What is Agios Pharmaceuticals Inc's earnings per share (EPS)?
Agios Pharmaceuticals Inc (AGIO) reported diluted earnings per share of $7.12 for fiscal year 2025. This represents a -38.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Agios Pharmaceuticals Inc's EBITDA?
Agios Pharmaceuticals Inc (AGIO) had EBITDA of $472K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Agios Pharmaceuticals Inc's gross margin?
Agios Pharmaceuticals Inc (AGIO) had a gross margin of 88.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Agios Pharmaceuticals Inc's operating margin?
Agios Pharmaceuticals Inc (AGIO) had an operating margin of 873.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Agios Pharmaceuticals Inc's net profit margin?
Agios Pharmaceuticals Inc (AGIO) had a net profit margin of 764.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Agios Pharmaceuticals Inc's return on equity (ROE)?
Agios Pharmaceuticals Inc (AGIO) has a return on equity of 34.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Agios Pharmaceuticals Inc's free cash flow?
Agios Pharmaceuticals Inc (AGIO) generated $369K in free cash flow during fiscal year 2025. This represents a 100.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Agios Pharmaceuticals Inc's operating cash flow?
Agios Pharmaceuticals Inc (AGIO) generated $373K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Agios Pharmaceuticals Inc's total assets?
Agios Pharmaceuticals Inc (AGIO) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Agios Pharmaceuticals Inc's capital expenditures?
Agios Pharmaceuticals Inc (AGIO) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Agios Pharmaceuticals Inc spend on research and development?
Agios Pharmaceuticals Inc (AGIO) invested $340K in research and development during fiscal year 2025.
How many shares does Agios Pharmaceuticals Inc have outstanding?
Agios Pharmaceuticals Inc (AGIO) had 59M shares outstanding as of fiscal year 2025.
What is Agios Pharmaceuticals Inc's current ratio?
Agios Pharmaceuticals Inc (AGIO) had a current ratio of 11.46 as of fiscal year 2025, which is generally considered healthy.
What is Agios Pharmaceuticals Inc's debt-to-equity ratio?
Agios Pharmaceuticals Inc (AGIO) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Agios Pharmaceuticals Inc's return on assets (ROA)?
Agios Pharmaceuticals Inc (AGIO) had a return on assets of 31.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Agios Pharmaceuticals Inc's Altman Z-Score?
Agios Pharmaceuticals Inc (AGIO) has an Altman Z-Score of 9308.87, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Agios Pharmaceuticals Inc's Piotroski F-Score?
Agios Pharmaceuticals Inc (AGIO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Agios Pharmaceuticals Inc's earnings high quality?
Agios Pharmaceuticals Inc (AGIO) has an earnings quality ratio of 0.90x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Agios Pharmaceuticals Inc?
Agios Pharmaceuticals Inc (AGIO) scores 83 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.